在充血性心力衰竭中,近端与远端利尿剂对比
Massimo Nardone1, Vikas S Sridhar1, Kevin Yau1
1University Health Network, Division of Nephrology, Department of Medicine, University of Toronto, Ontario, Canada.
概括
循环利尿剂是心力衰竭 (HF) 体积过载的基础. 新的辅助利尿剂,如SGLT2抑制剂和MR抗剂,显示出有前途,多脏向增强HF治疗.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
背景情况:
- 体积过载是心力衰竭 (HF) 进展的关键因素.
- 循环利尿剂是管理HF体积过载的主要治疗方法.
- 目前正在研究新兴疗法,以加强体积管理.
研究的目的:
- 审查各种利尿剂在急性和慢性心力衰竭中管理体积过载中的作用.
- 探索辅助利尿剂的机制和疗效,包括SGLT2抑制剂和MR抗剂.
- 评估多脏细分方法在治疗急性HF中循环利尿性耐药性的潜力.
主要方法:
- 关于心力衰竭中的利尿疗法的当前文献的综述.
- 对SGLT2抑制剂,MR抗剂,碳酸酶抑制剂, thiazide利尿剂的证据分析.
- 审查协同效应和独特的脏片段向.
主要成果:
- SGLT2 抑制剂和MR 抗剂在慢性心肌炎中提供长期心脏保护,尽管机制需要澄清.
- 在急性HF中,SGLT2抑制剂,碳酸 anhydrase 抑制剂和 thiazide 利尿剂可促进尿,但需要研究长期影响.
- 结合作用于不同脏段的利尿剂,可增强急性HF体积过载的利尿作用.
结论:
- 辅助性利尿剂,如SGLT2抑制剂和MR抗剂,在慢性HF治疗中具有价值.
- 需要进一步研究特定的利尿剂在急性HF的长期益处.
- 多脏细分策略对于在急性心力衰竭中管理体积过载是有效的,特别是在利尿剂耐药的情况下.
相关概念视频
01:22Heart Failure Drugs: Diuretics
375
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
375
01:15Antihypertensive Drugs: Thiazide-Class Diuretics
632
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
632
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
545
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
545
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
429
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
429
01:16Antihypertensive Drugs: Action of Diuretics
690
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
690
01:22Heart Failure Drugs: β-Blockers
338
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
338